Vanguard Group Inc. Acquires 330,823 Shares of Zoetis Inc. $ZTS

Vanguard Group Inc. raised its holdings in Zoetis Inc. (NYSE:ZTS) by 0.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 41,886,987 shares of the company’s stock after acquiring an additional 330,823 shares during the period. Vanguard Group Inc. owned approximately 9.45% of Zoetis worth $6,532,276,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Nova Wealth Management Inc. purchased a new stake in Zoetis in the first quarter valued at approximately $25,000. 1248 Management LLC bought a new position in shares of Zoetis in the 1st quarter worth $27,000. Saudi Central Bank purchased a new stake in shares of Zoetis during the 1st quarter valued at $29,000. REAP Financial Group LLC raised its position in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC lifted its holdings in shares of Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.4%

Shares of NYSE:ZTS opened at $118.30 on Wednesday. The stock has a market capitalization of $52.13 billion, a P/E ratio of 20.36, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The stock’s 50-day moving average price is $139.63 and its 200-day moving average price is $150.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $117.09 and a 12-month high of $181.85.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the prior year, the business posted $1.58 EPS. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio is 33.67%.

Analyst Ratings Changes

ZTS has been the topic of a number of research analyst reports. BTIG Research reduced their target price on Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research note on Wednesday, November 12th. Argus reiterated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Stifel Nicolaus decreased their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday. Morgan Stanley dropped their target price on Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, November 10th. Finally, UBS Group cut their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Zoetis currently has a consensus rating of “Moderate Buy” and a consensus target price of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.